ADVERTISEMENT

Suraksha Diagnostic Raises Rs 253 Crore From Anchor Investors Prior To IPO Launch

Suraksha Diagnostic allotted 57 lakh shares at ₹441 each to 16 anchor investors, with seven domestic mutual funds securing 67.36% of the anchor allocation.

<div class="paragraphs"><p>Suraksha Diagnostic raised ₹253.87 crore from anchor investors, with top allocations to Nippon India Pharma Fund and Kotak Small Cap Fund ahead of its ₹846.25 crore IPO.</p></div><div class="paragraphs"><p>Representative image for diagnostic sector (Unsplash)</p></div>
Suraksha Diagnostic raised ₹253.87 crore from anchor investors, with top allocations to Nippon India Pharma Fund and Kotak Small Cap Fund ahead of its ₹846.25 crore IPO. Representative image for diagnostic sector (Unsplash)

Suraksha Diagnostic Ltd. has raised Rs 253.87 crore from anchor investors on Thursday, ahead of its initial public offering. The company allotted 57 lakh shares at Rs 441 apiece to 16 anchor investors.

Nippon Life India Trustee Ltd.-A/C Nippon India Pharma Fund RCT-RPF and Kotak Small Cap got the highest allocation of 13.79%. Carnelian Bharat Amritkaal Fund got the second highest allotment of 11.82%, and Aditya Birla Sun Life Trustee Private Ltd. A/C Aditya Birla Sun Life Pharma & Healthcare Fund got a 9.93% stake in the company.

Seven domestic mutual funds have applied through 11 schemes, the diagnostic chain said in an exchange filing on Thursday. They have collectively netted 67.36% of the anchor portion.

Kotak, Aditya Birla, Mirae, and Nippon were among the top fund houses in this category.

Opinion
Agarwal Toughened Glass India IPO Opens Today: Check Price Band, Offer Size, GMP And Key Financials

ICICI Securities Ltd., Nuvama Wealth Management Ltd., and SBI Capital Markets Ltd. are the book-running lead managers to the issue.

The company will launch its initial public offering on Thursday to raise up to Rs 846.25 crore. The company has set a price band of Rs 420-441 per share for its three-day IPO, which only comprises an offer for the sale of 1.92 crore shares. The minimum application lot size is 34 shares.

The offer, which concludes on Tuesday, is set to list on the BSE and the National Stock Exchange.

The company will not receive any proceeds from the IPO, as the issue consists solely of an offer for sale. The entire proceeds will be received by Somnath Chatterjee, Ritu Mittal, and Satish Kumar Verma. Meanwhile, OrbiMed Asia II Mauritius Limited, Munna Lal Kejriwal, and Santosh Kumar Kejriwal, the promoters, are offloading their stake.

Incorporated in 2005, Suraksha Diagnostic is a diagnostic chain in Eastern India, providing a wide range of medical testing services like pathology, radiology testing, and medical consultancy services.

Opinion
C2C Advanced Systems IPO Allotment Expected Soon: Check Status, GMP And Other Key Details Here
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit